Trial Profile
An Early-Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) In Pediatric and Young Adult Patients With Previously Treated Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Hodgkin's disease; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdoid tumour; Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Acronyms iMATRIX; iMATRIX-atezo
- Sponsors Roche
- 25 Nov 2019 Results published in the Lancet Oncology.
- 09 Sep 2019 Status changed from active, no longer recruiting to discontinued.
- 17 Jul 2019 This trial has been completed in Italy, according to European Clinical Trials Database